{"protocolSection": {"identificationModule": {"nctId": "NCT01068652", "orgStudyIdInfo": {"id": "INS-3782"}, "secondaryIdInfos": [{"id": "U1111-1112-6407", "type": "OTHER", "domain": "WHO"}], "organization": {"fullName": "Novo Nordisk A/S", "class": "INDUSTRY"}, "briefTitle": "Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs", "officialTitle": "Effect of 50-week Treatment With Stepwise Insulin Intensification of Basal-bolus Insulin Analogues (Insulin Detemir and Aspart) or Biphasic Insulin Aspart 30 (NovoMix 30) All in Combination With Fixed Dose of Metformin on Glycaemic Control (Measured as HbA1c) in Subjects With Type 2 Diabetes. Open Labelled, Randomized, Two-arm, Parallel Group, Multi-centre, Multi-national Trial"}, "statusModule": {"statusVerifiedDate": "2016-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-03"}, "primaryCompletionDateStruct": {"date": "2012-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-02-12", "studyFirstSubmitQcDate": "2010-02-12", "studyFirstPostDateStruct": {"date": "2010-02-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-02-26", "resultsFirstSubmitQcDate": "2013-02-26", "resultsFirstPostDateStruct": {"date": "2013-04-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-11-23", "lastUpdatePostDateStruct": {"date": "2017-01-13", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novo Nordisk A/S", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This trial is conducted in Africa. The aim of this clinical trial is to investigate the effect of 50 weeks of treatment with different intensified insulin administrations (all in combination with a fixed dose of metformin) on blood sugar control in subjects with type 2 diabetes inadequately controlled by oral anti-diabetic drugs (OADs)."}, "conditionsModule": {"conditions": ["Diabetes", "Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 403, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Detemir + Met", "type": "ACTIVE_COMPARATOR", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached.", "interventionNames": ["Drug: insulin detemir", "Drug: insulin aspart", "Drug: metformin"]}, {"label": "BIAsp 30 + Met", "type": "ACTIVE_COMPARATOR", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.", "interventionNames": ["Drug: biphasic insulin aspart 30", "Drug: metformin"]}], "interventions": [{"type": "DRUG", "name": "insulin detemir", "description": "Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).", "armGroupLabels": ["Detemir + Met"]}, {"type": "DRUG", "name": "insulin aspart", "description": "Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)", "armGroupLabels": ["Detemir + Met"]}, {"type": "DRUG", "name": "biphasic insulin aspart 30", "description": "Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily", "armGroupLabels": ["BIAsp 30 + Met"]}, {"type": "DRUG", "name": "metformin", "description": "1000-2000 mg/day in combination with insulin treatment", "armGroupLabels": ["BIAsp 30 + Met", "Detemir + Met"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Glycosylated Haemoglobin (HbA1c)", "description": "Estimated mean difference in HbA1c after 50 weeks of treatment", "timeFrame": "Week 50"}], "secondaryOutcomes": [{"measure": "Change in Glycosylated Haemoglobin (HbA1c) After 14 Weeks of Treatment", "description": "Observed mean change from baseline in HbA1c at Week 14 (visit 11)", "timeFrame": "Week 0, Week 14"}, {"measure": "Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment", "description": "Observed mean change in from baseline in HbA1c at Week 26 (visit 18)", "timeFrame": "Week 0, Week 26"}, {"measure": "Change in Glycosylated Haemoglobin (HbA1c) After 38 Weeks of Treatment", "description": "Observed mean change from baseline in HbA1c at Week 38 (visit 25)", "timeFrame": "Week 0, Week 38"}, {"measure": "Change in Glycosylated Haemoglobin (HbA1c) at Week 50", "description": "Observed mean change from baseline in HbA1c at Week 50 (visit 32)", "timeFrame": "Week 0, Week 50"}, {"measure": "Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 14 Weeks of Treatment", "description": "Number of subjects achieving HbA1c below 7.0% after 14 weeks of treatment (visit 11)", "timeFrame": "Week 14"}, {"measure": "Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 26 Weeks of Treatment", "description": "Number of subjects achieving HbA1c below 7.0% after 26 weeks of treatment (visit 18)", "timeFrame": "Week 26"}, {"measure": "Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 38 Weeks of Treatment", "description": "Number of subjects achieving HbA1c below 7.0% after 38 weeks of treatment (visit 25)", "timeFrame": "Week 38"}, {"measure": "Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 50 Weeks of Treatment", "description": "Number of subjects achieving HbA1c below 7.0% after 50 weeks of treatment (visit 32)", "timeFrame": "Week 50"}, {"measure": "Mean of Prandial Plasma Glucose (PG) Increment After 14 Weeks of Treatment", "description": "Observed overall mean of PG increment after 14 weeks of treatment (Visit 11). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}", "timeFrame": "Week 14"}, {"measure": "Mean of Prandial Plasma Glucose (PG) Increment After 26 Weeks of Treatment", "description": "Observed overall mean of PG increment after 26 weeks of treatment (visit 18). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}", "timeFrame": "Week 26"}, {"measure": "Mean of Prandial Plasma Glucose (PG) Increment After 38 Weeks of Treatment", "description": "Observed overall mean of PG increment after 38 weeks of treatment (visit 25). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}.", "timeFrame": "Week 38"}, {"measure": "Mean of Prandial Plasma Glucose (PG) Increment After 50 Weeks of Treatment", "description": "Observed overall mean of PG increment after 50 weeks of treatment (visit 32). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}.", "timeFrame": "Week 50"}, {"measure": "Mean of 8-point Plasma Glucose (PG) Profile After 14 Weeks of Treatment", "description": "Observed overall mean of 8-point PG profile after 14 weeks of treatment (visit 11)", "timeFrame": "Week 14"}, {"measure": "Mean of 8-point Plasma Glucose (PG) Profile After 26 Weeks of Treatment", "description": "Observed overall mean of 8-point PG profile after 26 weeks of treatment (visit 18)", "timeFrame": "Week 26"}, {"measure": "Mean of 8-point Plasma Glucose (PG) Profile After 38 Weeks of Treatment", "description": "Observed overall mean of 8-point PG profile after 38 weeks of treatment (visit 25)", "timeFrame": "Week 38"}, {"measure": "Mean of 8-point Plasma Glucose (PG) Profile After 50 Weeks of Treatment", "description": "Observed overall mean of 8-point PG profile after 50 weeks of treatment (visit 32)", "timeFrame": "Week 50"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject)\n* Diagnosed type 2 diabetes (WHO 1999 criteria)\n* Currently treated with suboptimal daily dose of OADs (mono or combination therapy) for at least 6 months\n* Male or female age at least 18 years old\n* HbA1c at least 7.0 % and maximum 11.0% for subjects treated with metformin mono-therapy, or maximum 10% for subjects treated with OAD combination therapy\n* BMI maximum 40 kg/m\\^2\n* Able and willing to perform self-monitoring of plasma glucose according to the protocol and to keep a diary\n* Able and willing to be treated with up to 4 insulin injections per day\n\nExclusion Criteria:\n\n* Known or suspected allergy to trial product(s) or related products\n* Previous participation in this trial. Participation is defined as randomisation\n* Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice)\n* Participated in another clinical trial and received an investigational drug within the last weeks prior to the present trial\n* Impaired hepatic function defined as alanine aminotransferase (ALT) or alkaline phosphatase (ALP) at least 2.5 times upper referenced limit\n* Impaired renal function defined as serum-creatinine at least 1.3 mg/dL (at least 115 mmol/L) for males and at least 1.2 mg/dL (at least 106 mmol/L) for females\n* Subject has a clinically significant, active (or over the past 12 months) cardiovascular history (including a history of myocardial infarction (MI), arrhythmias or conduction delays on ECG, unstable angina, or decompensated heart failure (New York Heart Association class III and IV)\n* Severe uncontrolled treated or untreated hypertension (sitting systolic blood pressure at least 180 mmHg or sitting diastolic blood pressure at least 100 mmHg)\n* Proliferative retinopathy or macular oedema requiring acute treatment\n* Metformin contraindications according to the package insert\n* Current treatment with systemic corticosteroids\n* Subject has a history of any illness that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering study drug to the subject\n* Current addiction to alcohol or other addictive substances as determined by the Investigator\n* Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation in the study or use of the glucose monitor\n* History of hypoglycaemic unawareness and/or two or more severe hypoglycaemic episodes in the past year as judged by the Investigator", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Global Clinical Registry (GCR, 1452)", "affiliation": "Novo Nordisk A/S", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novo Nordisk Investigational Site", "city": "Ain T\u00e9mouchent", "zip": "46000", "country": "Algeria", "geoPoint": {"lat": 35.29749, "lon": -1.14037}}, {"facility": "Novo Nordisk Investigational Site", "city": "Alger", "zip": "16000", "country": "Algeria", "geoPoint": {"lat": 36.73225, "lon": 3.08746}}, {"facility": "Novo Nordisk Investigational Site", "city": "Algiers", "zip": "16000", "country": "Algeria", "geoPoint": {"lat": 36.73225, "lon": 3.08746}}, {"facility": "Novo Nordisk Investigational Site", "city": "Constantine", "zip": "25000", "country": "Algeria", "geoPoint": {"lat": 36.365, "lon": 6.61472}}, {"facility": "Novo Nordisk Investigational Site", "city": "Oran", "zip": "31000", "country": "Algeria", "geoPoint": {"lat": 35.69906, "lon": -0.63588}}, {"facility": "Novo Nordisk Investigational Site", "city": "Setif", "zip": "19000", "country": "Algeria", "geoPoint": {"lat": 36.19112, "lon": 5.41373}}, {"facility": "Novo Nordisk Investigational Site", "city": "Sidi Bel Abbes", "zip": "22000", "country": "Algeria", "geoPoint": {"lat": 35.18994, "lon": -0.63085}}, {"facility": "Novo Nordisk Investigational Site", "city": "Alexandria", "zip": "21131", "country": "Egypt", "geoPoint": {"lat": 31.21564, "lon": 29.95527}}, {"facility": "Novo Nordisk Investigational Site", "city": "Casablanca", "zip": "20000", "country": "Morocco", "geoPoint": {"lat": 33.58831, "lon": -7.61138}}, {"facility": "Novo Nordisk Investigational Site", "city": "Port Elizabeth", "state": "Eastern Cape", "zip": "6014", "country": "South Africa", "geoPoint": {"lat": -33.91799, "lon": 25.57007}}, {"facility": "Novo Nordisk Investigational Site", "city": "Johannesburg", "state": "Gauteng", "zip": "1812", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}, {"facility": "Novo Nordisk Investigational Site", "city": "Pretoria", "state": "Gauteng", "zip": "0002", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"facility": "Novo Nordisk Investigational Site", "city": "Pretoria", "state": "Gauteng", "zip": "0083", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"facility": "Novo Nordisk Investigational Site", "city": "Vaderbijlpark", "state": "Gauteng", "zip": "1900", "country": "South Africa"}, {"facility": "Novo Nordisk Investigational Site", "city": "Durban", "state": "KwaZulu-Natal", "zip": "4170", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Novo Nordisk Investigational Site", "city": "Durban", "state": "KwaZulu-Natal", "zip": "4450", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Novo Nordisk Investigational Site", "city": "Kimberly", "state": "Northern Cape", "zip": "8301", "country": "South Africa"}, {"facility": "Novo Nordisk Investigational Site", "city": "Cape Town", "state": "Western Cape", "zip": "7945", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Novo Nordisk Investigational Site", "city": "Sandton", "zip": "2146", "country": "South Africa", "geoPoint": {"lat": -26.05524, "lon": 28.05943}}, {"facility": "Novo Nordisk Investigational Site", "city": "Tunisia", "zip": "1053", "country": "Tunisia"}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Clinical Trials at Novo Nordisk", "url": "http://novonordisk-trials.com"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "The trial was conducted at 23 sites in 4 countries: Egypt (1), Algeria (9), Tunisia (4) and South Africa (9). The trial consisted of two weeks of screening, three weeks of run-in, and 50 weeks of treatment.", "groups": [{"id": "FG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "FG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "200"}, {"groupId": "FG001", "numSubjects": "203"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "182"}, {"groupId": "FG001", "numSubjects": "188"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "15"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Withdrawal criteria", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Patient was not eligible", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Unclassified", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "BG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "200"}, {"groupId": "BG001", "value": "203"}, {"groupId": "BG002", "value": "403"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.0", "spread": "9.0"}, {"groupId": "BG001", "value": "52.6", "spread": "10.1"}, {"groupId": "BG002", "value": "52.8", "spread": "9.6"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "113"}, {"groupId": "BG001", "value": "128"}, {"groupId": "BG002", "value": "241"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "87"}, {"groupId": "BG001", "value": "75"}, {"groupId": "BG002", "value": "162"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "54"}, {"groupId": "BG001", "value": "58"}, {"groupId": "BG002", "value": "112"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "29"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "37"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "112"}, {"groupId": "BG001", "value": "113"}, {"groupId": "BG002", "value": "225"}]}]}]}, {"title": "Glycosylated haemoglobin (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of glycosylated haemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.6", "spread": "1.1"}, {"groupId": "BG001", "value": "8.7", "spread": "1.1"}, {"groupId": "BG002", "value": "8.7", "spread": "1.1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Glycosylated Haemoglobin (HbA1c)", "description": "Estimated mean difference in HbA1c after 50 weeks of treatment", "populationDescription": "Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 20 subjects, HbA1c values were missing.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of glycosylated haemoglobin", "timeFrame": "Week 50", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.34", "spread": "0.13"}, {"groupId": "OG001", "value": "7.23", "spread": "0.12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To investigate the effect of different treatments, an analysis of covariance (ANCOVA) model was used to analyse HbA1c at week 50 with treatment group (2 categories: insulin detemir and aspart; BIAsp 30), country and pre-trial OAD(s) treatment (one OAD vs. more OADs) as factors and HbA1c at baseline (week 0) as a covariate. The treatment difference was estimated and a 95% confidence interval (CI) for the difference was calculated.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "The treatment comparison was based on a non-inferiority criterion and the following hypotheses were tested: H0: \u03bcDetemir - \u03bcBIAsp 30 \u22650.4% against the alternative hypothesis (Detemir non-inferior to BIAsp 30) HA: \u03bcDetemir - \u03bcBIAsp 30 \\<0.4% where \u03bcBIAsp 30 and \u03bcDetemir are the mean HbA1c after 50 weeks of treatment with the two treatment regimens.", "pValue": "0.3406", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.11", "ciPctValue": "95", "ciLowerLimit": "-0.12", "ciUpperLimit": "0.34"}]}, {"type": "SECONDARY", "title": "Change in Glycosylated Haemoglobin (HbA1c) After 14 Weeks of Treatment", "description": "Observed mean change from baseline in HbA1c at Week 14 (visit 11)", "populationDescription": "Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 20 subjects, values for change in HbA1c were missing.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of glycosylated haemoglobin", "timeFrame": "Week 0, Week 14", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.18", "spread": "1.16"}, {"groupId": "OG001", "value": "-0.64", "spread": "1.12"}]}]}]}, {"type": "SECONDARY", "title": "Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment", "description": "Observed mean change in from baseline in HbA1c at Week 26 (visit 18)", "populationDescription": "Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 20 subjects, values for change in HbA1c were missing.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of glycosylated haemoglobin", "timeFrame": "Week 0, Week 26", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.05", "spread": "1.05"}, {"groupId": "OG001", "value": "-1.30", "spread": "1.28"}]}]}]}, {"type": "SECONDARY", "title": "Change in Glycosylated Haemoglobin (HbA1c) After 38 Weeks of Treatment", "description": "Observed mean change from baseline in HbA1c at Week 38 (visit 25)", "populationDescription": "Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 20 subjects, values for change in HbA1c were missing.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of glycosylated haemoglobin", "timeFrame": "Week 0, Week 38", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.35", "spread": "1.16"}, {"groupId": "OG001", "value": "-1.56", "spread": "1.39"}]}]}]}, {"type": "SECONDARY", "title": "Change in Glycosylated Haemoglobin (HbA1c) at Week 50", "description": "Observed mean change from baseline in HbA1c at Week 50 (visit 32)", "populationDescription": "Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 20 subjects, values for change in HbA1c were missing.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of glycosylated haemoglobin", "timeFrame": "Week 0, Week 50", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.16", "spread": "1.33"}, {"groupId": "OG001", "value": "-1.34", "spread": "1.40"}]}]}]}, {"type": "SECONDARY", "title": "Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 14 Weeks of Treatment", "description": "Number of subjects achieving HbA1c below 7.0% after 14 weeks of treatment (visit 11)", "populationDescription": "Full Analysis Set (FAS) includes all randomised subjects. For 20 subjects, values were missing.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "Week 14", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "26"}]}]}]}, {"type": "SECONDARY", "title": "Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 26 Weeks of Treatment", "description": "Number of subjects achieving HbA1c below 7.0% after 26 weeks of treatment (visit 18)", "populationDescription": "Full Analysis Set (FAS) includes all randomised subjects. For 29 subjects, values were missing.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "185"}, {"groupId": "OG001", "value": "189"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "77"}]}]}]}, {"type": "SECONDARY", "title": "Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 38 Weeks of Treatment", "description": "Number of subjects achieving HbA1c below 7.0% after 38 weeks of treatment (visit 25)", "populationDescription": "Full Analysis Set (FAS) includes all randomised subjects. For 31 subjects, values were missing.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "Week 38", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "184"}, {"groupId": "OG001", "value": "188"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "103"}]}]}]}, {"type": "SECONDARY", "title": "Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 50 Weeks of Treatment", "description": "Number of subjects achieving HbA1c below 7.0% after 50 weeks of treatment (visit 32)", "populationDescription": "Full Analysis Set (FAS) includes all randomised subjects. For 35 subjects, values were missing.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "Week 50", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}, {"groupId": "OG001", "value": "187"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "84"}]}]}]}, {"type": "SECONDARY", "title": "Mean of Prandial Plasma Glucose (PG) Increment After 14 Weeks of Treatment", "description": "Observed overall mean of PG increment after 14 weeks of treatment (Visit 11). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}", "populationDescription": "Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 28 subjects, PG (mg/dL) increment values were missing at all evaluations.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 14", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "188"}, {"groupId": "OG001", "value": "187"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "43.19", "spread": "33.64"}, {"groupId": "OG001", "value": "32.61", "spread": "31.99"}]}]}]}, {"type": "SECONDARY", "title": "Mean of Prandial Plasma Glucose (PG) Increment After 26 Weeks of Treatment", "description": "Observed overall mean of PG increment after 26 weeks of treatment (visit 18). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}", "populationDescription": "Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 19 subjects, PG (mg/dL) increment values were missing at all evaluations.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "192"}, {"groupId": "OG001", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "32.95", "spread": "30.25"}, {"groupId": "OG001", "value": "31.71", "spread": "27.86"}]}]}]}, {"type": "SECONDARY", "title": "Mean of Prandial Plasma Glucose (PG) Increment After 38 Weeks of Treatment", "description": "Observed overall mean of PG increment after 38 weeks of treatment (visit 25). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}.", "populationDescription": "Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 19 subjects, PG (mg/dL) increment values were missing at all evaluations.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 38", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "192"}, {"groupId": "OG001", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25.44", "spread": "27.95"}, {"groupId": "OG001", "value": "28.32", "spread": "30.69"}]}]}]}, {"type": "SECONDARY", "title": "Mean of Prandial Plasma Glucose (PG) Increment After 50 Weeks of Treatment", "description": "Observed overall mean of PG increment after 50 weeks of treatment (visit 32). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}.", "populationDescription": "Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF). For 19 subjects, PG (mg/dL) increment values were missing at all evaluations.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 50", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "192"}, {"groupId": "OG001", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22.45", "spread": "25.50"}, {"groupId": "OG001", "value": "23.66", "spread": "28.91"}]}]}]}, {"type": "SECONDARY", "title": "Mean of 8-point Plasma Glucose (PG) Profile After 14 Weeks of Treatment", "description": "Observed overall mean of 8-point PG profile after 14 weeks of treatment (visit 11)", "populationDescription": "Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 14", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "200"}, {"groupId": "OG001", "value": "203"}]}], "classes": [{"title": "Before Breakfast (n=193, 194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "136.44", "spread": "42.86"}, {"groupId": "OG001", "value": "128.31", "spread": "33.58"}]}]}, {"title": "120 min After Breakfast (n=187, 184)", "categories": [{"measurements": [{"groupId": "OG000", "value": "181.89", "spread": "54.42"}, {"groupId": "OG001", "value": "176.31", "spread": "44.50"}]}]}, {"title": "Before Lunch (n=192, 193)", "categories": [{"measurements": [{"groupId": "OG000", "value": "157.61", "spread": "53.43"}, {"groupId": "OG001", "value": "156.12", "spread": "51.57"}]}]}, {"title": "120 min After Lunch (n=186, 185)", "categories": [{"measurements": [{"groupId": "OG000", "value": "199.40", "spread": "64.38"}, {"groupId": "OG001", "value": "199.75", "spread": "59.04"}]}]}, {"title": "Before Dinner (n=191, 192)", "categories": [{"measurements": [{"groupId": "OG000", "value": "169.69", "spread": "54.91"}, {"groupId": "OG001", "value": "168.09", "spread": "59.58"}]}]}, {"title": "120 min After Dinner (n=183, 185)", "categories": [{"measurements": [{"groupId": "OG000", "value": "212.23", "spread": "61.45"}, {"groupId": "OG001", "value": "173.95", "spread": "54.86"}]}]}, {"title": "Bedtime (n=187, 192)", "categories": [{"measurements": [{"groupId": "OG000", "value": "200.15", "spread": "60.83"}, {"groupId": "OG001", "value": "156.65", "spread": "50.65"}]}]}, {"title": "At 2 AM - 3 AM (n=172, 177)", "categories": [{"measurements": [{"groupId": "OG000", "value": "158.69", "spread": "50.06"}, {"groupId": "OG001", "value": "139.93", "spread": "43.39"}]}]}]}, {"type": "SECONDARY", "title": "Mean of 8-point Plasma Glucose (PG) Profile After 26 Weeks of Treatment", "description": "Observed overall mean of 8-point PG profile after 26 weeks of treatment (visit 18)", "populationDescription": "Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "200"}, {"groupId": "OG001", "value": "203"}]}], "classes": [{"title": "Before Breakfast (n=193, 194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "116.57", "spread": "34.40"}, {"groupId": "OG001", "value": "115.79", "spread": "27.23"}]}]}, {"title": "120 min After Breakfast (n=191, 191)", "categories": [{"measurements": [{"groupId": "OG000", "value": "163.52", "spread": "50.02"}, {"groupId": "OG001", "value": "153.85", "spread": "42.68"}]}]}, {"title": "Before Lunch (n=193, 194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "140.97", "spread": "49.96"}, {"groupId": "OG001", "value": "131.27", "spread": "42.85"}]}]}, {"title": "120 min After Lunch (n=191, 191)", "categories": [{"measurements": [{"groupId": "OG000", "value": "166.00", "spread": "57.15"}, {"groupId": "OG001", "value": "178.92", "spread": "51.14"}]}]}, {"title": "Before Dinner (n=192, 194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "147.58", "spread": "48.90"}, {"groupId": "OG001", "value": "143.29", "spread": "45.50"}]}]}, {"title": "120 min After Dinner (n=188, 191)", "categories": [{"measurements": [{"groupId": "OG000", "value": "172.21", "spread": "57.34"}, {"groupId": "OG001", "value": "152.44", "spread": "45.53"}]}]}, {"title": "Bedtime (n=190, 194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "164.70", "spread": "63.68"}, {"groupId": "OG001", "value": "140.39", "spread": "42.71"}]}]}, {"title": "At 2 AM - 3 AM (n=181, 187)", "categories": [{"measurements": [{"groupId": "OG000", "value": "133.59", "spread": "47.54"}, {"groupId": "OG001", "value": "123.29", "spread": "35.16"}]}]}]}, {"type": "SECONDARY", "title": "Mean of 8-point Plasma Glucose (PG) Profile After 38 Weeks of Treatment", "description": "Observed overall mean of 8-point PG profile after 38 weeks of treatment (visit 25)", "populationDescription": "Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 38", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "200"}, {"groupId": "OG001", "value": "203"}]}], "classes": [{"title": "Before Breakfast (n=193, 194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "110.14", "spread": "30.64"}, {"groupId": "OG001", "value": "110.86", "spread": "27.11"}]}]}, {"title": "120 min After Breakfast (n=191, 192)", "categories": [{"measurements": [{"groupId": "OG000", "value": "146.70", "spread": "44.11"}, {"groupId": "OG001", "value": "139.38", "spread": "42.74"}]}]}, {"title": "Before Lunch (n=193, 194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "130.63", "spread": "42.17"}, {"groupId": "OG001", "value": "118.30", "spread": "40.28"}]}]}, {"title": "120 min After Lunch (n=191, 192)", "categories": [{"measurements": [{"groupId": "OG000", "value": "145.91", "spread": "51.38"}, {"groupId": "OG001", "value": "158.45", "spread": "47.70"}]}]}, {"title": "Before Dinner (n=193, 194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "132.26", "spread": "41.90"}, {"groupId": "OG001", "value": "129.10", "spread": "43.84"}]}]}, {"title": "120 min After Dinner (n=192,192)", "categories": [{"measurements": [{"groupId": "OG000", "value": "155.47", "spread": "49.09"}, {"groupId": "OG001", "value": "142.82", "spread": "50.47"}]}]}, {"title": "Bedtime (n=193, 194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "146.37", "spread": "51.58"}, {"groupId": "OG001", "value": "132.45", "spread": "43.54"}]}]}, {"title": "At 2 AM - 3 AM (n=187, 190)", "categories": [{"measurements": [{"groupId": "OG000", "value": "124.57", "spread": "42.11"}, {"groupId": "OG001", "value": "117.42", "spread": "35.60"}]}]}]}, {"type": "SECONDARY", "title": "Mean of 8-point Plasma Glucose (PG) Profile After 50 Weeks of Treatment", "description": "Observed overall mean of 8-point PG profile after 50 weeks of treatment (visit 32)", "populationDescription": "Full analysis set (FAS) includes all randomised subjects and missing data is imputed using last observation carried forward (LOCF).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 50", "groups": [{"id": "OG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached."}, {"id": "OG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "200"}, {"groupId": "OG001", "value": "203"}]}], "classes": [{"title": "Before Breakfast (n=193, 194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "108.78", "spread": "31.10"}, {"groupId": "OG001", "value": "110.76", "spread": "22.08"}]}]}, {"title": "120 min After Breakfast (n=191, 192)", "categories": [{"measurements": [{"groupId": "OG000", "value": "140.05", "spread": "40.98"}, {"groupId": "OG001", "value": "132.45", "spread": "35.55"}]}]}, {"title": "Before Lunch (n=193, 194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "120.43", "spread": "37.62"}, {"groupId": "OG001", "value": "115.02", "spread": "36.20"}]}]}, {"title": "120 min After Lunch (n=191, 192)", "categories": [{"measurements": [{"groupId": "OG000", "value": "139.48", "spread": "49.03"}, {"groupId": "OG001", "value": "149.90", "spread": "44.32"}]}]}, {"title": "Before Dinner (n=193, 194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "128.28", "spread": "40.63"}, {"groupId": "OG001", "value": "126.76", "spread": "40.16"}]}]}, {"title": "120 min After Dinner (n=192, 192)", "categories": [{"measurements": [{"groupId": "OG000", "value": "144.19", "spread": "49.24"}, {"groupId": "OG001", "value": "138.08", "spread": "42.11"}]}]}, {"title": "Bedtime (n=193, 194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "137.13", "spread": "51.18"}, {"groupId": "OG001", "value": "130.10", "spread": "43.08"}]}]}, {"title": "At 2 AM - 3 AM (n=187, 190)", "categories": [{"measurements": [{"groupId": "OG000", "value": "118.60", "spread": "40.65"}, {"groupId": "OG001", "value": "113.14", "spread": "35.21"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "The adverse events were collected in a time frame of 0-50 weeks + 2 weeks follow-up", "description": "Safety analysis set includes all subjects who received at least one dose of the investigational product or its comparator", "eventGroups": [{"id": "EG000", "title": "Detemir + Met", "description": "Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. \\[under the skin\\]) if treatment target of HbA1c below 7.0% was not reached.", "seriousNumAffected": 13, "seriousNumAtRisk": 200, "otherNumAffected": 75, "otherNumAtRisk": 200}, {"id": "EG001", "title": "BIAsp 30 + Met", "description": "Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.", "seriousNumAffected": 7, "seriousNumAtRisk": 203, "otherNumAffected": 78, "otherNumAtRisk": 203}], "seriousEvents": [{"term": "Splenomegaly", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 203}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}]}, {"term": "Cholecystitis chronic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}]}, {"term": "Excoriation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}]}, {"term": "Foot fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}]}, {"term": "ECG signs of myocardial ischaemia", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}]}, {"term": "Weight decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}]}, {"term": "Pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 203}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}]}, {"term": "Diabetic foot", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 203}]}], "otherEvents": [{"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 16, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 11, "numAffected": 11, "numAtRisk": 203}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 13, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 20, "numAffected": 15, "numAtRisk": 203}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 15, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 20, "numAffected": 17, "numAtRisk": 203}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 10, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 13, "numAffected": 11, "numAtRisk": 203}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 13, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 12, "numAffected": 12, "numAtRisk": 203}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 200}, {"groupId": "EG001", "numEvents": 14, "numAffected": 12, "numAtRisk": 203}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication."}, "pointOfContact": {"title": "Public Access to Clinical Trials", "organization": "Novo Nordisk A/S", "email": "clinicaltrials@novonordisk.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007328", "term": "Insulin"}, {"id": "C000557859", "term": "Insulin, Globin Zinc"}, {"id": "D000008687", "term": "Metformin"}, {"id": "D000061267", "term": "Insulin Aspart"}, {"id": "D000049528", "term": "Insulin, Long-Acting"}, {"id": "C000578220", "term": "Insulin degludec, insulin aspart drug combination"}, {"id": "D000069057", "term": "Insulin Detemir"}, {"id": "D000061265", "term": "Biphasic Insulins"}, {"id": "C000557564", "term": "Insulin aspart, insulin aspart protamine drug combination 30:70"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M349", "name": "Insulin Detemir", "asFound": "Oocyte", "relevance": "HIGH"}, {"id": "M29801", "name": "Insulin Aspart", "asFound": "Obtained", "relevance": "HIGH"}, {"id": "M29799", "name": "Biphasic Insulins", "asFound": "Institutional", "relevance": "HIGH"}, {"id": "M17768", "name": "Zinc", "relevance": "LOW"}, {"id": "M26073", "name": "Insulin, Long-Acting", "asFound": "Obtained", "relevance": "HIGH"}, {"id": "M117006", "name": "Insulin degludec, insulin aspart drug combination", "asFound": "Obtained", "relevance": "HIGH"}, {"id": "M14342", "name": "Protamines", "relevance": "LOW"}, {"id": "M350709", "name": "Insulin aspart, insulin aspart protamine drug combination 30:70", "asFound": "One side", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Micro", "name": "Micronutrients"}, {"abbrev": "Coag", "name": "Coagulants"}]}}, "hasResults": true}